Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 2 of 2
Full-Text Articles in Respiratory Therapy
Case Report: Dementia Sensitivity To Altitude Changes And Effective Treatment With Hyperbaric Air And Glutathione Precursors, Edward F. Fogarty, Paul G. Harch
Case Report: Dementia Sensitivity To Altitude Changes And Effective Treatment With Hyperbaric Air And Glutathione Precursors, Edward F. Fogarty, Paul G. Harch
School of Medicine Faculty Publications
A 78-year-old man with dementia experienced waxing and waning of symptoms with changes in altitude as he traveled from his home in the Rocky Mountains to lower elevations and back. To replicate the improvement in his symptoms with travel to lower elevations (higher pressure), the patient was treated with a near-identical repressurization in a hyperbaric chamber using compressed air. With four 1-h treatments at 1.3 Atmospheres Absolute (ATA) and concurrent administration of low-dose oral glutathione amino acid precursors, he recovered speech and showed improvement in activities of daily living. Regional broadcast media had documented his novel recovery. Nosocomial COVID-19 and …
Systematic Review And Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy In The Treatment Of Posttraumatic Stress Disorder, Susan R. Andrews, Paul G. Harch
Systematic Review And Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy In The Treatment Of Posttraumatic Stress Disorder, Susan R. Andrews, Paul G. Harch
School of Medicine Faculty Publications
Background: Studies of hyperbaric oxygen therapy (HBOT) treatment of mild traumatic brain injury persistent postconcussion syndrome in military and civilian subjects have shown simultaneous improvement in posttraumatic stress disorder (PTSD) or PTSD symptoms, suggesting that HBOT may be an effective treatment for PTSD. This is a systematic review and dosage analysis of HBOT treatment of patients with PTSD symptoms. Methods: PubMed, CINAHL, and the Cochrane Systematic Review Database were searched from September 18 to November 23, 2023, for all adult clinical studies published in English on HBOT and PTSD. Randomized trials and studies with symptomatic outcomes were selected for final …